Skip to content
Screener

Vir Biotechnology, Inc. VIR Q2 2026 earnings

Reported August 5, 2026 · After market close

Revenue$238.9MBeat by $103.1M
EPS$0.47Beat by $0.14
Revenue estimate$135.9M
EPS estimate$0.33
“This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts emphasized that achieving durable suppression of hepatitis delta virus to undetectable levels is a key predictor of improved clinical outcomes for people with CHD. Our Week 96 SOLSTICE results demonstrate the potential of our dual-acting elebsiran and tobevibart combination regimen to rapidly achieve undetectable virus in most patients and raise the bar for treatment of this devastating condition. Beyond CHD, we remain focused on rapid execution of our joint clinical program with Astellas in prostate cancer and have initiated monotherapy and combination therapy dose-expansion cohorts in our VIR-5500 Phase 1 study that will help inform pivotal trial design.”
Marianne De Backer

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$865.1K
EPS estimate-$0.74

Financials

Q2 2026

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
CapEx$32.0K-98.7%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.78B+167%
Enterprise value$1.59B+243%
P/S5.9×-29.2×

Profitability

See full
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio6×-1.0×

Segments

By product

See full
License and collaboration revenue$238.9M—
Grant revenue$11.0K-94.0%
Other revenue-—

By segment

See full
Reportable Segment$238.9M+19,583%

FAQ

When did Vir Biotechnology, Inc. report Q2 2026 earnings?
Vir Biotechnology, Inc. (VIR) reported Q2 2026 earnings on August 5, 2026 after market close.
What were Vir Biotechnology, Inc.'s Q2 2026 revenue and EPS?
Vir Biotechnology, Inc. reported revenue of $238.9M and eps of $0.47 for Q2 2026.
Did Vir Biotechnology, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $135.9M by $103.1M. EPS beat the consensus estimate of $0.33 by $0.14.
How did Vir Biotechnology, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 19582.5% from $1.2M a year earlier.
Where can I find Vir Biotechnology, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-053351) and the 10-Q periodic report (0001628280-26-053549) directly on SEC EDGAR. The filing index links above go to sec.gov.